Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard S Oster

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
The Israel Medical Association Journal : IMAJ|November 28, 2006
Erythropoietin in clinical practice: current use, effect on survival, and future directionsHoward S Oster, Michael Hoffman, Sara Prutchi-Sagiv, et al.
Blood|October 18, 2021
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination settingMoshe Mittelman, Ori Magen, Noam Barda, et al.
European Journal of Haematology|January 4, 2025
Do we Need to Perform Bone Marrow Examination in all Subjects Suspected of MDS? Evaluation and Validation of Non-Invasive (Web-Based) Diagnostic AlgorithmHoward S Oster, Ariel M Polakow, Roi Gat, et al.
The Israel Medical Association Journal : IMAJ|October 17, 2018
Myelodysplastic Syndromes Over Time: A Comparison of Two Patient CohortsHoward S Oster, Shani Svorai-Litvak, Ilya Kirgner, et al.
Experimental Hematology|October 31, 2012
Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patientsHoward S Oster, Sara Prutchi-Sagiv, Ora Halutz, et al.
International Journal of Laboratory Hematology|January 29, 2024
Validation of a novel algorithm with a high specificity in ruling out MDSFelicitas Schulz, Kathrin Nachtkamp, Howard S Oster, et al.
Frontiers in Oncology|February 13, 2023
Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes - A potential prognostic marker?Reut Book, Jonathan Ben-Ezra, Chen Glait Santar, et al.
Leukemia Research|November 22, 2016
Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromesNaamit Deshet-Unger, Howard S Oster, Sara Prutchi-Sagiv, et al.
British Journal of Haematology|November 17, 2006
Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?Sara Prutchi-Sagiv, Natalia Golishevsky, Howard S Oster, et al.
Leukemia & Lymphoma|January 4, 2018
Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic modelHoward S Oster, Gal Carmi, Alex Kolomansky, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
The Israel Medical Association Journal : IMAJ|November 28, 2006
Erythropoietin in clinical practice: current use, effect on survival, and future directionsHoward S Oster, Michael Hoffman, Sara Prutchi-Sagiv, et al.
Blood|October 18, 2021
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination settingMoshe Mittelman, Ori Magen, Noam Barda, et al.
European Journal of Haematology|January 4, 2025
Do we Need to Perform Bone Marrow Examination in all Subjects Suspected of MDS? Evaluation and Validation of Non-Invasive (Web-Based) Diagnostic AlgorithmHoward S Oster, Ariel M Polakow, Roi Gat, et al.
The Israel Medical Association Journal : IMAJ|October 17, 2018
Myelodysplastic Syndromes Over Time: A Comparison of Two Patient CohortsHoward S Oster, Shani Svorai-Litvak, Ilya Kirgner, et al.
Experimental Hematology|October 31, 2012
Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patientsHoward S Oster, Sara Prutchi-Sagiv, Ora Halutz, et al.
International Journal of Laboratory Hematology|January 29, 2024
Validation of a novel algorithm with a high specificity in ruling out MDSFelicitas Schulz, Kathrin Nachtkamp, Howard S Oster, et al.
Frontiers in Oncology|February 13, 2023
Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes - A potential prognostic marker?Reut Book, Jonathan Ben-Ezra, Chen Glait Santar, et al.
Leukemia Research|November 22, 2016
Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromesNaamit Deshet-Unger, Howard S Oster, Sara Prutchi-Sagiv, et al.
British Journal of Haematology|November 17, 2006
Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?Sara Prutchi-Sagiv, Natalia Golishevsky, Howard S Oster, et al.
Leukemia & Lymphoma|January 4, 2018
Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic modelHoward S Oster, Gal Carmi, Alex Kolomansky, et al.
Pageof 4